scispace - formally typeset
Search or ask a question
Topic

Dalfopristin

About: Dalfopristin is a research topic. Over the lifetime, 696 publications have been published within this topic receiving 26621 citations. The topic is also known as: RP-54476 & Dalfopristina.


Papers
More filters
Journal ArticleDOI
TL;DR: Results from this study suggest that this broad-spectrum bacteriocin-producing strain may have a potential use in food preservation, and is called AS-48RJ.

79 citations

Journal ArticleDOI
TL;DR: A number of novel antimicrobial combinations that may be useful against staphylococci and enterococci are suggested and warrant further investigation for the treatment of refractive infections due to multidrug-resistant gram-positive pathogens.
Abstract: Use of combinations of antimicrobials that together achieve synergistic activities against targeted microorganisms is one potential strategy for overcoming bacterial resistance. As the incidence of infections caused by multidrug-resistant staphylococci and enterococci increases, the importance of devising additional synergistic drug combinations for these bacteria is magnified. We evaluated a number of antimicrobial combinations, with a focus on quinupristin-dalfopristin (Q-D), cefepime, and linezolid, using a previously described in vitro pharmacodynamic model. The combination of Q-D with either linezolid or vancomycin, as well as the combination of cefepime-vancomycin, resulted in enhanced killing (≥2-log10 increase in killing versus the most-active single agent) against methicillin-resistant Staphylococcus aureus (MRSA) 494. An improved effect (<2 log10 kill increase in kill) against MRSA 494 was noted for cefepime plus either Q-D or linezolid, as well as linezolid-vancomycin. Similar relationships were observed for a methicillin-susceptible S. aureus isolate (isolate 1199). Against methicillin-resistant S. epidermidis R444, enhanced killing was achieved with the combination of cefepime-linezolid, while improvement was noted for vancomycin with either cefepime or linezolid. The combination of cefepime and vancomycin also achieved enhanced killing against a glycopeptide-intermediate-susceptible S. aureus isolate (isolate 992). The combination of linezolid and doxycycline achieved an enhanced effect against vancomycin-resistant Enterococcus faecalis (VREFc) and E. faecium. Q-D plus ampicillin or linezolid resulted in similar enhancement of activity against the VREFc isolate. The results of this study suggest a number of novel antimicrobial combinations that may be useful against staphylococci and enterococci. Combination regimens including cefepime, Q-D, and/or linezolid warrant further investigation for the treatment of refractive infections due to multidrug-resistant gram-positive pathogens.

79 citations

Journal ArticleDOI
TL;DR: The in vitro activities of mupirocin, quinupristin/dalfopristin, linezolid, eperezolid, sitafloxacin, clinafloxacIn, moxifloxacsin, amoxycillin, metronidazole and clarithromycin were tested against 57 strains of Helicobacter pylori to find the most active and least active agents.
Abstract: The in vitro activities of mupirocin, quinupristin/dalfopristin, linezolid, eperezolid, sitafloxacin, clinafloxacin, moxifloxacin, amoxycillin, metronidazole and clarithromycin were tested at pH 7.4 against 57 strains of Helicobacter pylori. The most active agents (mupirocin, sitafloxacin and clinafloxacin) were also tested for activity at pH 5.4 against the same strains. Mupirocin was very active at pH 7.4 and 5.4 (MIC90 0.25 and 0.12 mg/L, respectively). Quinupristin/dalfopristin, linezolid and eperezolid had low activity (MIC90 4, 8 and 4 mg/L, respectively). Sitafloxacin (MIC90

78 citations

Journal ArticleDOI
TL;DR: The emergence of SREF is likely to be the result of an interaction between QD use in medicine and the long-term use of virginiamycin for animal growth promotion, which has created a credible threat to the efficacy of QD.
Abstract: Vancomycin-resistant enterococci (VRE) are an important cause of hospital-acquired infections and an emerging infectious disease. VRE infections were resistant to standard antibiotics until quinupristin/dalfopristin (QD), a streptogramin antibiotic, was approved in 1999 for the treatment of vancomycin-resistant Enterococcus faecium infections in people. After that decision, the practice of using virginiamycin in agriculture for animal growth promotion came under intense scrutiny. Virginiamycin, another streptogramin, threatens the efficacy of QD in medicine because streptogramin resistance in enterococci associated with food animals may be transferred to E faecium in hospitalised patients. Policy makers face an unavoidable conundrum when assessing risks for pre-emergent pathogens; good policies that prevent or delay adverse outcomes may leave little evidence that they had an effect. To provide a sound basis for policy, we have reviewed the epidemiology of E faecium and streptogramin resistance and present qualitative results from mathematical models. These models are based on simple assumptions consistent with evidence, and they establish reasonable expectations about the population-genetic and population-dynamic processes underlying the emergence of streptogramin-resistant E faecium (SREF). Using the model, we have identified critical aspects of SREF emergence. We conclude that the emergence of SREF is likely to be the result of an interaction between QD use in medicine and the long-term use of virginiamycin for animal growth promotion. Virginiamycin use has created a credible threat to the efficacy of QD by increasing the mobility and frequency of high-level resistance genes. The potential effects are greatest for intermediate rates of human-to-human transmission (R0 approximately equal 1).

78 citations

Journal ArticleDOI
TL;DR: faecal bacteria such as E. coli and enterococci of wild rabbits could be a reservoir of antimicrobial resistance genes, and resistance genes detected included aac(6')-aph(2''), ant(6)-Ia, tet(M) and/or tet(L) in all gentamicin, streptomycin and tetracycline-resistant isolates respectively.

78 citations


Network Information
Related Topics (5)
Antibacterial agent
35.8K papers, 1.2M citations
82% related
Antibiotic resistance
29.1K papers, 884.5K citations
82% related
Staphylococcus aureus
27K papers, 779K citations
81% related
Pseudomonas aeruginosa
16.8K papers, 565.2K citations
81% related
Drug resistance
28.4K papers, 1.1M citations
80% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20237
202217
20219
202010
201913
201811